Edwards' chance for fresh blood as CFO retires
This article was originally published in Clinica
Executive Summary
On the same day that stuttering heart valve specialist Edwards Lifesciences announced a $750 million share repurchase program in a bid to placate shareholders, its CFO said he would retire later this year. The departure of Thomas Abate, who has been at the company for 31 years and turns 60 in August, is “a bit surprising but understandable given recent misses and related stock performance”, said Jefferies analyst Raj Denhoy. It could even be a positive, giving Edwards chance to bring in fresh blood after a difficult period.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.